Non-alcoholic fatty liver disease (NAFLD) is caused by the build-up of lipids in the liver; over time, the condition can progress to increase the risk of developing cirrhosis, end-stage liver disease and hepatocellular carcinoma. NAFLD has become the most common chronic liver disease in high-income countries, affecting up to one-third of the general adult population [1] [2] [3] , and is on trajectory to become the most common indication for liver transplantation in the USA (it is currently the third most common indication) 4 . NAFLD is also the most rapidly growing indication for simultaneous liver-kidney transplantation 5 , which contributes to growing evidence indicating that NAFLD is not only associated with liver-related mortality and morbidity, but is a multisystem disease that affects multiple extra-hepatic organ systems, such as the kidneys and cardiovascular system 6 . Moreover, recognition of the strong relationship between NAFLD and the metabolic syndrome has stimulated considerable interest in the putative impact of NAFLD on the development and progression of chronic kidney disease (CKD) 7 . This disease, which is associated with high levels of morbidity and mortality, and high health-care costs across the globe 8 , is becoming increasingly common; in the USA, for example, more than 10% of the adult population (about 26 million people) and more than 25% of individuals older than 65 years have CKD 9 . NAFLD and CKD share multiple risk factors (such as abdominal obesity, insulin resistance, atherogenic dyslipidaemia, hypertension and dysglycaemia) and pathogenetic pathways 7, 10, 11 . The existence of mechanistic pathways linking the liver and kidneys is also supported by the presence of hepatorenal syndrome, which can develop in cirrhotic patients with portal hypertension.
NAFLD NAFLD is a term that encompasses a clinicopathological spectrum of liver diseases ranging from simple fatty infiltration in more than 5% of hepatocytes (simple hepatic steatosis), to fatty infiltration plus inflammation (non-alcoholic steatohepatitis; NASH), to advanced fibrosis and, ultimately, to cirrhosis that can progress to hepatocellular carcinoma 1, 3 .
Diagnosis of NAFLD
A diagnosis of NAFLD is based on three criteria: hepatic steatosis is visible on imaging or histology; alcohol consumption is not excessive (a threshold of 20 g per day for women and 30 g per day for men is conventionally adopted); and no competing causes for hepatic steatosis (such as viruses, drugs, iron overload or autoimmunity) exist 1, 3 .
Clinical signs. In general, clinical signs or symptoms of liver disease are absent from the majority of patients with NAFLD at the time of diagnosis; moderate hepatomegaly is often the only physical indication, although fatigue and a feeling of satiety or abdominal discomfort are reported by some patients. A considerable number of patients with NAFLD display typical features of metabolic syndrome (abdominal obesity, atherogenic dyslipidaemia, hypertension, insulin resistance, glucose intolerance or type 2 diabetes mellitus (T2DM)) 1, 3 . The presence of mildly to moderately elevated levels of serum liver enzymes (serum aminotransferases and γ-glutamyltransferase) is the most common -and often the only -laboratory abnormality found in patients with NAFLD; other laboratory abnormalities (for example, thrombocytopaenia, increased bilirubin levels and an increased prothrombin time) might be found in patients with more advanced forms of NAFLD (cirrhosis) 1, 3 . However, serum liver enzyme levels are not reliable indicators for the screening and diagnosis of NAFLD and should, therefore, not be used without further investigation in clinical practice; patients with fairly normal serum liver enzyme levels can display the full pathological spectrum of NAFLD 1, 3 .
Imaging and histology. Liver ultrasonography is the recommended first-line imaging modality for detecting NAFLD in clinical practice 1, 3 . On ultrasound, hepatic steatosis produces a typical diffuse increase in echogenicity (the so-called 'bright liver'). Ultrasonography detects the presence of mild and moderate-to-severe hepatic steatosis with good diagnostic accuracy, demonstrating a sensitivity and specificity, respectively, of approximately 85% and 95% (when liver fat infiltration is at least 20-30%) 12 . Moreover, ultrasonography is relatively inexpensive and might help clinicians to exclude other causes of liver disease and identify any early signs of cirrhosis or portal hypertension.
To date, T1-weighted dual-echo MRI and proton magnetic resonance spectroscopy define hepatic steatosis with the best diagnostic accuracy. Proton magnetic resonance spectroscopy enables quantitative assessment of the content of hepatic triglycerides and has excellent reproducibility and sensitivity, but is resource intensive and cannot reliably discriminate simple steatosis from NASH 1, 3 . The progression from simple steatosis through NASH to advanced fibrosis and the level and staging of fibrosis are of particular clinical interest, as complications associated with end-stage liver disease are known to arise in patients with NAFLD who have advanced fibrosis 1, 3 . Liver biopsy remains the standard procedure for diagnosing NASH and staging the degrees of hepatic necroinflammation and fibrosis in patients with more-advanced NAFLD, but this procedure is invasive, patient-unfriendly, potentially risky, and subject to sampling error, and is therefore unsuitable for patient monitoring or for diagnosis in large cohorts of individuals 1, 3 . A number of non-invasive biomarker tests, most of which require further validation, could be useful for identifying those patients with NAFLD who require a liver biopsy for disease staging. The sensitivity and specificity of these non-invasive tests for the assessment of advanced hepatic fibrosis have been described 13 . The NAFLD fibrosis score and the fibrosis (FIB)-4 score (which both include in their equations routine clinical and laboratory variables, such as age, levels of serum aminotransferases, serum albumin content, platelet count, body mass index or diabetes status) are examples of validated nonproprietary clinical scores for estimating advanced liver fibrosis, whereas the enhanced liver fibrosis (ELF) test and the FibroTest are examples of proprietary techniques that have been proposed for the non-invasive assessment of advanced liver fibrosis according to panels of specific serum biomarkers 13 . Another approach to staging hepatic fibrosis, known as FibroScan, measures the speed of a low-frequency elastic sheer wave as it propagates through the liver -the stiffer the tissue, the faster the shear wave propagates. However, in many cases (~20% of patients, mainly those who are obese), this ultrasonography-based transient elastography approach does not provide a reliable measure of liver stiffness, which thereby limits its use in obese patients with NAFLD 13, 14 .
Key points
• Accumulating evidence indicates that the presence and severity of non-alcoholic fatty liver disease (NAFLD) is strongly associated with an increased prevalence of chronic kidney disease (CKD) • The presence and severity of NAFLD predicts the development of incident CKD, independent of traditional cardiorenal risk factors • Evidence suggests that NAFLD exacerbates insulin resistance, predisposes to atherogenic dyslipidaemia, and causes the release of proinflammatory, procoagulant, pro-oxidant and profibrogenic mediators that are important in the pathophysiology of CKD • Despite the growing evidence linking NAFLD to CKD, whether a causal association exists has not been definitively established • These findings call for a more active and systematic search for NAFLD in patients with CKD with a view to potential earlier treatment Several other imaging techniques that assess liver stiffness, including 2D acoustic radiation force impulse imaging, shear-wave elastography and 3D magnetic resonance elastography, are being developed 14 . NAFLD in high-risk patients. On the basis of the available evidence and guidelines 3, 13 , together with our personal opinions, we have proposed a potential pragmatic algorithm for the diagnosis and monitoring of NAFLD in 'high-risk' individuals -those who have metabolic risk factors or CKD (FIG. 1) . It is important to emphasize that an intense debate on these aspects is ongoing, and that a validated, widely accepted, algorithm for the diagnosis and monitoring of NAFLD in this group of 'high-risk' individuals does not yet exist.
Epidemiology of NAFLD
Prevalence. Estimates of the prevalence of NAFLD vary according to the population that is studied (for example, patients with different ethnicities, sex and comorbid conditions) and the sensitivity of the method used for diagnosis of the disease (that is, biochemistry, imaging or histology).
A 2016 systematic review and meta-analysis of 86 studies (involving a total of ~8 million individuals from 22 countries) estimated that around a quarter of the world's adult population has NAFLD as diagnosed by imaging 15 . NAFLD was common throughout the world, but was particularly prevalent in South America (31%) and the Middle East (32%), whereas it showed a low prevalence in Africa (14%). This meta-analysis also confirmed previous findings that NAFLD is similarly prevalent in Europe and the USA (24%) 15 . The prevalence of NAFLD was much higher among 'high-risk' patients, such as those with T2DM (70-75%) or severe obesity (90-100%). As mentioned above, NASH can only be diagnosed by biopsy and thus the true prevalence of NASH in the general population cannot be easily estimated. This meta-analysis showed that the pooled regional prevalence estimates for NASH among patients with NAFLD who had an indication for biopsy were 64% for Asia, 69% for Europe, and 61% for North America 15 . By contrast, the estimates for the prevalence of NASH among patients with NAFLD without an indication for biopsy were approximately 7% for Asia and 30% for North America.
Incidence. Data on NAFLD incidence are scant and were obtained only for China, Japan and Israel in the above-described meta-analysis. Estimates for NAFLD incidence from pooled regions of Asia and Israel were approximately 52 per 1,000 person-years and 28 per 1,000 person-years, respectively 15 .
A link between NAFLD and CKD? Given the strong association of NAFLD with abdominal obesity, T2DM and other clinical features of metabolic syndrome 1, 3, 6 , it should come as no surprise that not only is cardiovascular disease (CVD) the leading cause of death in patients with NAFLD 3, 6 , but that a link also exists between NAFLD and CKD 7 .
NAFLD and increased CKD prevalence
In the past 5 years, several cross-sectional communitybased and hospital-based studies have consistently demonstrated that NAFLD, diagnosed either by imaging [16] [17] [18] [19] [20] [21] [22] [23] [24] or histology [25] [26] [27] [28] [29] , is associated with an increased prevalence of CKD (defined as the presence of a decreased estimated glomerular filtration rate (eGFR), abnormal albuminuria or overt proteinuria), regardless of diabetes status. In these studies, the prevalence of CKD in patients with NAFLD ranged from approximately 20% to 55%, compared to 5-30% in those without NAFLD [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Notably, in most of these studies, the association between NAFLD and CKD was independent of common cardiorenal risk factors across a wide range of patient populations. The finding of a significant and independent association between NAFLD and early kidney dysfunction (defined as microalbuminuria or eGFR <90 ml/min/1.73 m²) has also been confirmed in a single cohort of 596 children who were overweight or obese; renal dysfunction was more apparent among the 268 children who had NAFLD than among those who did not 30 . Recognition of early renal dysfunction in childhood or adolescence is clinically important because the treatment to reverse it is more likely to be effective if applied early in the disease process. Finally, some smaller case-control studies that used liver biopsy to diagnose NAFLD have also shown that a significant, graded relationship exists between the histological severity of NAFLD (principally the hepatic fibrosis stage) and the presence of either decreased kidney function or abnormal albuminuria [25] [26] [27] [28] [29] . However, it is important to underline that none of these studies used renal biopsy to examine the pathology of the CKD, so whether NAFLD is associated with a specific type of kidney disease is currently unknown.
NAFLD as a risk factor for CKD?
Although the associations between NAFLD and CKD from cross-sectional studies are strong and consistent across different patient populations, whether NAFLD is a new 'driving force' for the development and progression of CKD remains an issue of intense debate. Certainly, the validation of NAFLD as an independent risk factor for CKD would have direct potential relevance for the primary prevention of this disease.
In a community-based cohort of nearly 8,400 non-diabetic and non-hypertensive South Korean men with normal kidney function and no overt proteinuria at baseline who were followed for a mean of 3.2 years, NAFLD (diagnosed by ultrasonography) was associated with an increased incidence of CKD (adjusted HR 1.60; 95% CI 1.3-2.0) 31 . This finding was present after adjustment for body mass index, hypertension, insulin resistance, plasma C-reactive protein level, baseline eGFR and other potential confounding factors for CKD. In the Valpolicella Heart Diabetes Study of 1,760 patients with T2DM and preserved kidney function who were followed over a 6.5-year period, patients with NAFLD showed an increased incidence of CKD (HR 1.69; 95% CI 1.3-2.6) 32 . This finding was present after adjustment for age, sex, body mass index, waist circumference, blood pressure, smoking, duration of diabetes, glycosylated haemoglobin, lipids, baseline eGFR, microalbuminuria and use of antihypertensive, hypoglycaemic, antiplatelet and lipid-lowering medications 32 . Consistent with these findings, when 261 patients with T1DM and preserved kidney function with no overt proteinuria at baseline were followed for a mean period of 5.2 years, the presence of NAFLD on ultrasonography was associated with an increased incidence of CKD (HR 2.85, 95% CI 1.6-5.1), even after adjustment for age, sex, duration of diabetes, hypertension, glycosylated haemo globin and baseline eGFR, and after excluding those patients with microalbuminuria at baseline. Notably, adding NAFLD to the list of traditional risk factors for CKD considerably increased the discriminatory capability of the regression models to predict incident CKD 33 . A 2014 systematic review and meta-analysis of 33 studies (20 cross-sectional and 13 longitudinal studies, involving a total of nearly 64,000 individuals) examined the association between NAFLD and the risk of CKD 34 . NAFLD was diagnosed by biochemistry, imaging or histology, and CKD defined as either eGFR <60 ml/min/1.73 m 2 or overt proteinuria. NAFLD was associated with a twofold increase in the prevalence (OR 2.12, 95% CI 1.7-2.7) and a nearly twofold increase in the incidence (HR 1.79, 95% CI 1.7-1.9) of CKD in cross-sectional and longitudinal studies, respectively. Although NAFLD was diagnosed from biopsy samples in only a limited number of studies, the presence of NASH was associated with a higher prevalence (OR 2.53, 95% CI 1.6-4.1) and incidence (HR 2.12, 95% CI 1.4-3.2) of CKD than simple steatosis. Similarly, advanced hepatic fibrosis was associated with a higher prevalence (OR 5.20, 95% CI 3.1-8.6) and incidence (HR 3.29, 95% CI 2.3-4.7) of CKD than non-advanced fibrosis. In all of these analyses, the significant association between NAFLD and the increased risk of CKD persisted after adjustment for diabetes status and other traditional risk factors for CKD 34 .
Although the results of this meta-analysis provide robust evidence of a strong association between the presence and severity of NAFLD and the risk of CKD, it is important to emphasize that the quality of some of the published studies is limited, and that causality remains to be proven in high-quality intervention studies. Notably, the studies all used creatinine-based equations to estimate glomerular filtration rate (GFR), which do not perform well in patients with obesity or cirrhosis, instead of direct GFR measurements to define CKD. Furthermore, no detailed information was available in these studies about specific renal pathology and/or morphology associated with NAFLD. Additional prospective and intervention studies of longer duration and in larger cohorts of patients with histologically confirmed NAFLD than previously studied are needed to confirm these findings and to determine whether NAFLD might selectively contribute to the pathogenesis of different types of kidney disease, and to elucidate whether improvement in NAFLD will ultimately prevent or delay the development and progression of CKD. Taken together, however, the published studies clearly suggest that patients with NAFLD have a high risk of CKD and need more intensive surveillance and treatment to reduce their risk of developing CKD over time.
The pathophysiology of NAFLD and CKD A plethora of different factors and pathways are implicated in the pathogenesis of NAFLD and CKD (TABLE 1; Supplementary information S1 (table) ). Some, such as cardiometabolic risk factors, for example, might influence pathways in both the liver and the kidneys; other risk factors might influence pathways in the liver, and the consequent changes in the liver subsequently influence kidney structure and function; conversely, risk factors might influence pathways in the kidneys, and the consequent changes in the kidneys subsequently influence liver structure and function (FIG. 2 ). For example, many different factors are associated with a low-grade inflammatory response, a state that underpins the patient phenotype in many individuals with NAFLD, CKD, T2DM or CVD, and it is often difficult to know whether these different factors cause or arise as a consequence of the inflammation. In the case of NAFLD, various factors can contribute to the development of liver lipid accumulation (which defines NAFLD); as the liver disease progresses, additional factors come into play -for example, insulin resistance and endothelial cell activation -and it is plausible that these additional factors (rather than the liver lipid) could be responsible for causing hepatic inflammation. Deterioration of the liver subsequently has the potential to strongly influence extra-hepatic pathways and the structure and function of other organs and systems. For example, as NAFLD progresses from simple steatosis to NASH, deterioration of the liver might further influence the development of CKD, T2DM and CVD. NASH results in the production of multiple inflammatory mediators such as cytokines, lipopolysaccharides (LPS) and reactive oxygen species, which can lead to insulin resistance, endothelial dysfunction and a tissue inflammatory infiltrate, all of which could influence CKD. It is beyond the scope of this Review to discuss each of these factors and pathophysiological processes in detail, so we focus on the factors and pathways that we consider important in linking NAFLD and CKD. We begin with a brief discussion of the key factors involved in the pathogenesis of hepatic steatosis and NASH in NAFLD, before discussing factors linking NAFLD with CKD.
The pathogenesis of NAFLD
Factors that predispose to NAFLD. A number of environmental and physiological factors, including fructose consumption and excessive caloric intake, decreased vitamin D 3 levels, abdominal adiposity and insulin resistance, can promote the development of NAFLD. The most common cause of NAFLD is a caloric intake that exceeds caloric expenditure, resulting in a consequential spillover of surplus energy in the form of non-esterified fatty acids (NEFAs) from expanded visceral adipose tissue into ectopic fat depots, such as the liver.
Many different hepatic lipids can be found in NAFLD, but the condition is defined by the accumulation of triglycerides. Liver triglycerides accumulate when the rate of hepatic triglyceride synthesis exceeds the rates of hepatic triglyceride catabolism and triglyceride export as very-low-density lipoprotein particles 3, 6 . Approximately 60% of hepatic lipid derives from increased peripheral lipolysis of triglycerides (to yield glycerol, which can only be taken up by the liver), whereas dietary fats and sugars contribute approximately 35-40%. The liver can also contribute to steatosis by producing lipid from dietary carbohydrates through de novo lipogenesis 6 . The contribution of de novo lipogenesis to liver fat content is less than 5% in healthy individuals but might increase to approximately 25% in patients with NAFLD 35 . Accumulating evidence indicates that heritability is also important in determining variability in the susceptibility to NAFLD [1] [2] [3] . Genetic factors have been estimated to account for approximately half of the variability in hepatic fat content, and fibrosis tends to be inherited alongside steatosis. Genome-wide association studies have begun to reveal specific common genetic determinants of NAFLD; for example, the Ile148Met loss-of-function variant PNPLA3, which encodes a triglyceride lipase, confers an increased risk of NASH, cirrhosis and hepatocellular carcinoma [1] [2] [3] .
Factors that predispose to NASH. The increased intake of dietary fructose, particularly from sugary drinks, has become a major public health issue; it not only increases hepatic de novo lipogenesis 36 , thereby increasing the risk of NASH, but might also increase the serum concentration of uric acid 37 . Hyperuricaemia, in turn, might not only increase the risk of gout, but urinary excretion of uric acid might also further damage the kidneys in patients who are susceptible to CKD development 37 . With increased dietary calorie intake, and net positive energy balance, the expansion of intra-abdominal visceral adipose tissue releases increased amounts of NEFAs and proinflammatory molecules into the Increased amounts of non-esterified fatty acids (NEFAs) resulting from the expansion of intra-abdominal visceral adipose tissue are associated with an increase in NF-κB and inflammatory pathways, dysregulation of adipokine production leading to decreased adiponectin levels and impaired insulin signalling. Progression of liver dysfunction triggers pathways that might influence the development of CKD. For example, insulin resistance and atherogenic dyslipidaemia as well as proinflammatory factors, prothrombotic factors and profibrogenic molecules can promote vascular and renal damage. Reduced activation of the energy sensor, 5ʹ-AMP activated protein kinase (AMPK), in response to reduced adiponectin levels further stimulates proinflammatory and profibrogenic mechanisms. Activation of the renin-angiotensin system (RAS) and endothelial cells might also contribute to liver and kidney dysfunction by increasing oxidative stress, inflammation and coagulation pathways. Increased production of uraemic toxins by intestinal microbiota in the setting of CKD might induce further renal, liver and cardiovascular damage through inflammatory, oxidative and fibrotic pathways. Dysbiosis of the intestinal microbiota, which often occurs with obesity, potentially influences NAFLD, CKD, and type 2 diabetes mellitus (T2DM) through complex mechanisms. Finally, cardiovascular disease (CVD), the risk of which is increased in the setting of NAFLD, T2DM or intestinal dysbiosis, can influence the development of renal dysfunction (and vice versa) through cardiorenal interactions. AGE, advanced glycation end-product; NASH, nonalcoholic steatohepatitis; ROS, reactive oxygen species; SCFA, short-chain fatty acid; TMAO, trimethylamine oxide. vasculature 38, 39 . Inflammation of adipose tissue is one of the earliest events that can promote systemic insulin resistance. Proinflammatory pathways converge on two main intracellular transcription factor signalling pathways, the nuclear factor-κB (NF-κB) pathway and the c-Jun-amino-terminal kinase (JNK) pathway 40 , and data from animal studies indicate that JNK-1 activation might be involved in insulin resistance in the liver 41 . Furthermore, the accumulation of diacyl glycerol intermediates in hepatocytes that occurs during hepatic lipogenesis 42 impairs hepatic insulin signalling and fuels gluconeogenesis 42 , thereby promoting hyperglycaemia and predisposing to the development of T2DM 6 . In addition, increased levels of circulating and intracellular NEFAs are associated with an increase in NF-κB, leading to increased transcription of multiple proinflammatory cytokine genes in the liver and dysregulation of adipokine production by adipose tissue, such as decreased levels of adiponectin, which might also contribute to the progression of NAFLD 6 . The development of hepatic necroinflammation in NASH might result in the further release of several pathogenetic mediators into the systemic circulation from the steatotic and inflamed liver. Such mediators include reactive oxygen species, advanced glycation end-products (particularly in NAFLDassociated T2DM), C-reactive protein, plasminogen activator inhibitor-1, transforming growth factor-β and other proinflammatory and procoagulant factors, contributing to an increased risk of liver fibrosis, cirrhosis and vascular disease.
Mechanisms linking NAFLD with CKD
Many of the risk factors for NAFLD also have the potential to influence the development of CKD, and crosstalk between affected organs has the potential to cause further injury (FIG. 2; TABLE 1 ; Supplementary information S1 (table) ).
Visceral obesity, insulin resistance and inflammation.
An increase in visceral obesity or the accumulation of ectopic fat, together with insulin resistance, can favour the development of T2DM, which, in turn, increases the risk of developing liver disease, CKD and CVD. Insulin resistance has been suggested to contribute to the progression of kidney disease by worsening renal haemodynamics through activation of the sympathetic nervous system, sodium retention and downregulation of the natriuretic peptide system 43 , making insulin resistance a possible mechanistic link between NAFLD and CKD.
Activation of the NF-κB pathway in NASH increases the transcription of a variety of proinflammatory genes that can amplify systemic chronic inflammation 44, 45 , so the increased intra-hepatic cytokine production that occurs in more advanced forms of NAFLD is also likely to have a pathogenetic role in the development of extra-hepatic complications, such as CVD and CKD.
Although the presence of T2DM undoubtedly increases the risk of CVD in patients with NAFLD, several studies have shown that potential mediators of vascular and renal damage occur more frequently in patients with NAFLD, regardless of whether or not they also have T2DM [46] [47] [48] [49] . Increased levels of reactive oxygen species, oxidative stress and the inflammatory response are all thought to be important pathogenetic factors that are not only involved in the development of NASH, but are also significant in the development and progression of CKD. A study in patients with T2DM, with or without persistent hepatic inflammation (owing to chronic hepatitis B virus infection) suggested that the presence of liver inflammation is a key mediator of the increased risk of CKD. Patients with T2DM and chronic hepatitis B virus infection were more likely to develop endstage renal disease than were patients without hepatitis B virus infection 50 . Further support for the notion that liver inflammation (irrespective of its aetiology) is important in mediating a link between NAFLD and CKD comes from other studies that have investigated the known links between hepatitis C virus infection, atherosclerosis and kidney disease [51] [52] [53] .
Atherogenic dyslipidaemia, coagulation, endothelial cells and adiponectin.
A common feature of NAFLD is atherogenic dyslipidaemia, which is typically characterized by an increased number of small, dense LDL cholesterol particles, low levels of HDL cholesterol and increased plasma triglyceride concentrations. As athero genic dyslipidaemia is associated with increased risk of atherosclerotic vascular disease, the potential for renal endothelial dysfunction and renovascular damage also exists.
Increased levels of procoagulant factors and profibrogenic growth factors are also present in patients with NAFLD. NAFLD-related increases in components of the renin-angiotensin system, such as angiotensin II, can also contribute to vascular disease via increases in oxidative stress that block insulin signalling and accelerate atherosclerosis 54, 55 . Angiotensin II might also be involved in the progression of liver disease in NASH as it promotes the development of hepatic fibrosis 56, 57 . The activation of endothelial cells is often associated with chronic systemic inflammation, increased levels of reactive oxygen species and increased activity of coagulation pathways. These phenomena are known to be involved in vascular disease and might, therefore, also contribute to the development and progression of CKD through effects on renal endothelial cells [58] [59] [60] . Adiponectin is an adipose-tissue-secreted protein with anti-inflammatory and anti-atherogenic effects. Patients with NAFLD often have hypoadiponectinaemia. One study found that plasma adiponectin levels were inversely associated with the severity of NAFLD on histology, independent of other important confounding factors 61 , although this finding was not confirmed in another study in which adiponectin was not related to NAFLD severity but to hepatic insulin resistance 62 . An interesting hypothesis supports a role for crosstalk between adiponectin and fetuin-A, a liversecreted protein that promotes insulin resistance and regulates adiponectin levels 63 . Decreased plasma adiponectin levels reduce activation of the energy sensor 5ʹ-AMP activated protein kinase (AMPK), thereby stimulating proinflammatory and profibrogenic mechanisms in hepatocytes and podocytes, consequently causing liver and kidney damage 63 .
Gut microbiota and intestinal dysbiosis.
Intestinal dysbiosis refers to perturbation of the normal intestinal microbiota such that both qualitative and quantitative changes occur. Dysbiosis can potentially influence NAFLD, CKD and obesity through multiple and complex mechanisms (FIGS 2,3) . Dysbiosis, which often occurs with obesity 64 , has been described in patients with T2DM [65] [66] [67] [68] , NAFLD 69, 70 and CKD 71, 72 . For example, in NAFLD, an abundance of Bacteroides species is independently associated with NASH, whereas Ruminococcus species are associated with significant liver fibrosis 70 . T2DM and NAFLD are often accompanied by 'functional' dysbiosis, in which changes in microbial species (such as Akkermantia muciniphila and Faecalibacterium prausnitzii) affect the metabolic and proinflammatory pathways that influence gut oxidative stress and butyrate production [73] [74] [75] [76] .
Increased amounts of Akkermantia muciniphila are also associated with higher activity of intestinal neuroendocrine L cells, resulting in increased production of glucagon-like peptide-1 (GLP-1), which might improve insulin secretion and increase satiety 77 . As obesity and insulin resistance are important risk factors for NAFLD, vascular disease, and CKD, improvements in insulin secretion (and glucose tolerance), and the induction of weight loss facilitated by increased satiety are likely to be beneficial. Dysbiosis is also suggested to occur in CKD, and the most commonly reported changes in the gut microbiome of patients with CKD relate to lower levels of Bifidobacteriaceae and Lactobacillaceae and to higher levels of Enterobacteriaceae 71 . Microbial fermentation of dietary fibre in the intestine by anaerobic bacteria such as Lactobacilli and Bifidobacteria results in the formation of short-chain fatty acids (SFCAs) including acetate, propionate and butyrate, which have the potential to influence hepatic lipogenesis and gluconeogenesis. Decreased levels of SCFAs in the setting of NAFLD might therefore Figure 3 | Potential mechanisms by which intestinal dysbiosis might promote the development of non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). An imbalance in intestinal microbiota (dysbiosis) resulting in an increase in Gram-negative bacteria leads to an increase in lipopolysaccharide (LPS) production, which can damage the intestinal epithelium resulting in increased gut permeability. This increased gut permeability enables further egress of bacterial content, LPS and small molecules into the portal and systemic circulations causing inflammation. Dysbiosis also promotes the increased production of secondary bile acids such as deoxycholic acid. Following their return to the liver as part of the enterohepatic circulation, secondary bile acids have been linked to chronic inflammation, cholestasis and carcinogenesis through their actions on farnesoid X Receptor (FXR; with downstream effects on cholesterol metabolism) and by inducing cellular senescence and causing damage to mitochondrial and cell membranes. The intestinal microbiota also generates molecules such as trimethylamine (TMA), p-cresol and indole from dietary choline, phenylalanine/tyrosine and tryptophan, respectively. TMA is oxidized in the liver to trimethylamine oxide (TMAO), which promotes atherosclerotic vascular disease. Indole and p-cresol are metabolised in the liver to indole sulphate and p-cresol sulphate, which are cleared by the proximal tubules and are potentially nephrotoxic. Other molecules produced by microbiota metabolism, such as phenylacetic acid and hippuric acid, are also potentially toxic to the kidney. Reduced levels of short-chain fatty acids (SCFAs) as a consequence of dysbiosis can also induce decreased lipogenesis and increased gluconeogenesis, leading to insulin resistance, further dysfunction of the liver and kidney, and to the development of type 2 diabetes mellitus (T2DM). contribute to the development of liver adiposity and hepatic insulin resistance [78] [79] [80] . The SCFA receptor, free fatty acid receptor 2 (FFA2) is present on colonic entero-endocrine L cells and intra-colonic administration of propionate in rodents has been shown to stimulate release of the incretins peptide YY (PYY) and GLP-1 from L cells 81 . Increased levels of PYY and GLP-1 improve satiety and increase insulin secretion, respectively 81 . Some bacteria, such as those from the Clostridium, Eubacterium, and Butyrivibrio genera, can produce butyrate in the gut lumen at millimolar levels; butyrate provides an energy source for colonic cells, protecting against autophagy, and is a critical modulator of the colonic inflammatory response 82, 83 . These bacteria can also produce intermediates such as formate, lactate and succinate, which facilitate further bacterial growth.
Dysbiosis is also frequently associated with an increased production from Gram-negative bacteria of endotoxins (LPS), which can damage the intestinal barrier, affect vitamin absorption and increase gut permeability by disrupting intracellular tight junctions. Consequently, LPS, cytokines and gut microbiota DNA can potentially be released into the circulation and the liver. LPS also promotes inflammation within the liver and the resultant systemic inflammation might contribute to an increased risk of CKD. Primary bile acids, such as chenodeoxycholic acid and cholic acid, are influenced in three ways by gut microbiota to generate potentially harmful secondary bile acids, such as urodeoxycholic acid, deoxycholic acid (DCA) and lithocholic acid 79, 84 . Secondary bile acids are highly hydrophobic and toxic. The influence of bile acid metabolism on the kidneys is uncertain, but increased concentrations in the liver have been linked to inflammation, cholestasis and carcinogenesis 85 . Secondary bile acids might exert toxic effects that have the potential to influence the development and progression of NAFLD in two ways. First, they can increase intestinal permeability by decreasing the efficacy of tight junctions; this increased permeability can facilitate the direct transfer of LPS products to the liver, as outlined above. Alternatively, the hydrophobicity of secondary bile acids enables their interaction with phospholipids in the cell membranes of hepatocytes, thereby perturbing mitochondrial membranes. Although the causal implications of the effects of secondary bile acids are uncertain, studies in mice suggest that increased levels of the secondary bile acid DCA might have a deleterious impact in the liver 84 . DCA is produced solely by the 7α-dehydroxylation of primary bile acids by gut bacteria, and the enterohepatic circulation of DCA provokes DNA damage and consequent cellular senescence in hepatic stellate cells which, in turn, secrete various inflammatory and tumour-promoting factors in the liver, thus facilitating the development of hepatocellular carcinoma 84 . Evidence thereby indicates that subtle alteration of bile acid metabolism by intestinal microbiota could influence the development and progression of NAFLD.
Further evidence supporting the notion that modifications to bile acids can affect the liver is provided by the results of the farnesoid X nuclear receptor (FXR) ligand obeticholic acid in patients with noncirrhotic NASH (FLINT) trial 86 . In this trial, treatment with obeticholic acid, an FXR-agonist created by adding an ethyl group to chenodeoxycholic acid, produced an improvement in liver histology in approximately 45% of patients with biopsy-confirmed NASH 86 . The precise mechanism by which FXR activation with obeticholic acid led to a benefit in some but not all patients is unclear. However, studies in mice suggest that activation of FXR with obeticholic acid inhibits intestinal cholesterol absorption by modulating the size and composition of the bile acid pool, thus increasing reverse cholesterol transport 87 . Theoretically, such changes might decrease the risk of atherosclerosis and CKD, but further studies are needed to test this hypothesis.
The intestinal microbiota also generates molecules such as trimethylamine, p-cresol and indole from dietary nutrients such as choline, phenylalanine/tyrosine and tryptophan, respectively. Further metabolism in the liver by oxidation or sulphation generates ionically charged water-soluble molecules, such as trimethylamine-N-oxide (TMAO), p-cresol sulphate and indole sulphate, which can be excreted in the urine. Indole sulphate, which is cleared by the proximal tubules, is proinflammatory (it is associated with NF-κB activation) and potentially toxic to the kidneys as it increases the risk of tubulointerstitial fibrosis 72 . Other examples of molecules produced by the intestinal microbiota and excreted in the urine that are potentially toxic are phenylacetic acid and hippuric acid. TMAO has been shown to induce liver oxidative damage and atherosclerosis, probably through upregulation of atherogenic macrophage scavenger receptors and the formation of foam cells 88 . Increased systemic TMAO levels might also adversely affect the kidneys and inhibition of TMAO production might benefit the kidneys and vasculature 89 . Plasma levels of TMAO are increased and associated with poorer long-term survival outcomes in patients with CKD 90 . In animal studies, diets that increase circulating levels of TMAO might contribute to progressive renal fibrosis and dysfunction 90 .
Managing and treating NAFLD To date, no large studies have examined the use of medications and lifestyle modification in patients with both NAFLD and CKD. However, because NAFLD and CKD share multiple cardiometabolic risk factors and common pathogenetic pathways, it is reasonable to assume that prevention and treatment strategies for NAFLD and CKD are similar, sharing the specific aims of improving insulin resistance and modifying all the coexisting cardio metabolic risk factors. In theory, if NAFLD is identified as a risk factor in the development of CKD, then strategies aimed at ameliorating NAFLD should prevent or delay the development and progression of CKD.
Although no approved pharmacological agents are currently available for the treatment of NAFLD, several are under investigation on the basis of the biological mechanisms discussed above [91] [92] [93] . Promising novel agents with anti-inflammatory, antifibrotic or insulin-sensitizing properties (for example, dual peroxisome-proliferator-activated receptor (PPAR)-α/δ . The current therapeutic approach to patients with NAFLD is multifactorial 1, 3, 91, 92 , beginning with modifications aimed at mediating weight loss (FIG. 4) .
Diet and lifestyle modifications
The mainstay of management for NAFLD is lifestyle intervention, which includes a hypocaloric diet and regular physical exercise; a 5-10% reduction in body weight is associated with improvements in hepatic steatosis and necroinflammation 1, 3, [91] [92] [93] . Resistance exercise might be more feasible than aerobic exercise for patients with NAFLD who have poor cardiorespiratory fitness or who cannot tolerate or participate in aerobic exercise. Notably, in a cohort of 261 patients with histologically confirmed NASH who were treated with lifestyle modification for 52 weeks, those with NASH resolution or with improved and/or stabilized hepatic fibrosis were more likely to improve or stabilize their kidney function, compared to those without NASH resolution or with impaired fibrosis, when adjusted by weight-loss categories 95 . Bariatric surgery (an effective nonpharmacological treatment to decrease body weight in patients with severe obesity) markedly improves all histological lesions of NASH, including hepatic fibrosis 1, 3, 91, 92 ; however, limitations to this approach -including complications, patient acceptability, service availability and costs -exist.
Pharmacotherapy
At the moment, pharmacotherapy for NAFLD should probably be reserved for patients with NASH (particularly those with substantial fibrosis or with metabolic risk factors), who are at the highest risk for disease progression 1, 3, 91, 92 . However, no specific pharmacotherapy can be firmly recommended and any drug treatment would be off-label, as no drug has yet been tested in phase 3 trials or approved for NASH by regulatory agencies.
Pioglitazone. Randomized clinical trials have documented that treatment of patients with biopsy-confirmed NASH with pioglitazone (a highly selective PPARγ agonist that improves systemic and hepatic insulin sensitivity) reduces hepatic steatosis and necroinflammation, but not hepatic fibrosis, and that withdrawal of this treatment might determine the reappearance of liver damage 1, 3, 91, 92 . A randomized, double-blind trial involving 101 patients with T2DM or pre-diabetes and biopsy-proven NASH who received either 45 mg per day of pioglitazone or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment, reported that 51% of patients treated with pioglitazone showed resolution of NASH 96 . Pioglitazone treatment was also associated with reduced intrahepatic triglyceride content and improved systemic and hepatic insulin sensitivity. All 18-month metabolic and histologic improvements persisted over 36 months of therapy 96 . Despite these encouraging data, pioglitazone is not licensed for the treatment of NASH, and concerns regarding fluid retention, weight gain, risk of bone fractures and, to a lesser extent, bladder cancer have meant that the long-term use of pioglitazone in patients with NASH remains limited.
Obeticholic acid. As previously mentioned, the FXR ligand and insulin-sensitizing agent obeticholic acid is an interesting novel agent. In a multicentre, randomized, placebo-controlled trial of 283 individuals with noncirrhotic NASH, treatment with obeticholic acid (25 mg daily) for 72 weeks significantly improved the biochemical and histological features of NASH (including hepatic steatosis, necroinflammation and fibrosis) compared with placebo 86 . However, this drug is not well tolerated and can generate adverse effects, such as cholestasis with itching (in about 25% of treated patients) and a substantial increase in total and LDL cholesterol concentrations 86 .
GLP-1 agonists. Preliminary evidence arising from some retrospective, observational studies and a randomized phase 2 clinical trial suggests some beneficial effects of GLP-1 agonists such as liraglutide and exenatide on the levels of serum liver enzymes and histological features of NASH; whether these benefits derive from concurrent weight loss brought about by the actions of GLP-1 agonists on insulin is uncertain 3, 91, 92, 97, 98 . The most common The first approach is the treatment of overweight and obese patients through appropriate changes in lifestyle or, in cases of severe obesity, bariatric surgery. This step is followed by the optimization of glycaemic control in patients with established diabetes mellitus and the treatment of all coexisting cardiometabolic risk factors, which might be accompanied by the use of therapies that potentially have beneficial effects on the liver. The main goals of treatment are threefold: to improve hepatic/peripheral insulin sensitivity; to reduce intra-hepatic fat infiltration; and to avoid the progression of nonalcoholic steatohepatitis to more severe histological forms (cirrhosis, liver failure and hepatocellular carcinoma (HCC)), which will require management/treatment in their own right.
adverse events leading to the discontinuation of treatment with GLP-1 agonists are gastrointestinal events. Further evidence is required to support the efficacy of these new antihyperglycaemic drugs in NASH.
Metformin. Studies using the diabetes drug metformin for the treatment of NAFLD have produced conflicting results. These studies indicate that metformin has beneficial effects on serum liver enzymes and insulin resistance, but has no beneficial effect on liver histology. Thus, metformin is not currently recommended as a specific treatment for liver disease in patients with NASH 1, 3, 91, 92 .
Statins and other lipid-lowering agents. In several largescale trials, statins have been shown to be effective at reducing CVD-associated morbidity and mortality 99 . Although concerns over liver toxicity might previously have limited the use of statins in patients with NAFLD, current data indicate that statins can be safely used to treat dyslipidaemia in patients with NASH 1, 3 , and might also reduce the number of CVD events and mortality associated with NAFLD 100, 101 . Data regarding the effects of statins on liver histology in patients with NAFLD are limited and controversial, but statin use has been shown to be associated with protection against the full spectrum of liver damage in individuals at risk of NASH 102 . Consistent with this view, statins are also hypothesized to be associated with a reduced risk of hepatocellular carcinoma 103 . To date, however, no large randomized clinical trials have tested the long-term effects of statins on histological liver end points in patients with NAFLD.
Post hoc analyses of randomized controlled trials have shown that atorvastatin might confer nephroprotection in dyslipidaemic patients with CVD and normal renal function at baseline 104, 105 . A meta-analysis has also shown that use of statins decreases all-cause and cardiovascular mortality and major CVD events in patients with CKD not requiring dialysis 106 . However, current KDIGO guidelines state that treatment with statins should not be initiated in patients with dialysis-dependent CKD as, despite the high risk of CVD in this patient population, the benefits are uncertain 107 . Proprotein convertase subtilisin kexin type 9 (PCSK9) has a key role in the regulation of cholesterol homeo stasis. By binding to hepatic LDL receptors and promoting their lysosomal degradation, PCSK9 reduces hepatic LDL uptake, leading to an increase in LDL cholesterol concentration 108 . The development of PCSK9 inhibitors for the management of hypercholesterolaemia has attracted considerable attention and it would be extremely interesting to examine the potential effects of PCSK9 inhibitors on liver histology in patients with NAFLD.
Anti-hypertensive agents. Although no randomized clinical trials have specifically examined the effects of different antihypertensive agents on liver histology in patients with hypertension and NASH, inhibitors of the renin-angiotensin system should be the first-line choice in the treatment of these patients. The potential antifibrogenic effect of these drugs is becoming increasingly recognized in both animal and human studies 51 .
In preliminary clinical trials, losartan or valsartan improved insulin sensitivity, and reduced the levels of serum liver enzymes and other surrogate markers of NASH, whereas telmisartan reduced hepatic necroinflammation and fibrosis 109, 110 . Moreover, in a cross-sectional study of 290 hypertensive patients with biopsy-confirmed NAFLD, the use of renin-angiotensin system blockers was associated with less advanced hepatic fibrosis, providing further evidence that the renin-angiotensin system might be involved in NAFLD pathogenesis 111 . Similarly, in a cross-sectional study of 191 patients with CKD with or without NAFLD, the use of renin-angiotensin system blockers was associated with a lower degree of liver stiffness in patients with NAFLD as measured by ultrasonography-based transient elastography 112 . At present, however, no robust data with histological end points as a primary outcome are available to formally comment on the effectiveness of renin-angiotensin system blockers as a specific treatment for NASH 1, 3, 91, 92 .
Antioxidants. Given that increased oxidative stress occurs in NAFLD, another therapeutic option might be to decrease oxidative stress using an antioxidant, such as vitamin E 1, 3, 91, 92 . In the pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis (PIVENS) trial, which involved 247 nondiabetic patients with histologically confirmed NASH, treatment with vitamin E (at a dose of 800 U per day for 96 weeks), as compared with placebo, was associated with a significant reduction in serum liver enzyme levels and an improvement in some histological features of NASH 113 . However, before vitamin E can be recommended for the treatment of NASH, further evidence is required to support efficacy and, importantly, the safety of this fat-soluble agent. Similarly, although vitamin E or other antioxidant treatments do not reduce the risk of all-cause and cardiovascular death or major CVD events in patients with CKD, further appropriately powered studies with longer follow-up are needed 114 . Pentoxifylline has been also shown to decrease oxidative stress and inhibit lipid oxidation. Some small clinical trials have examined the use of pentoxifylline for the treatment of NAFLD, and have documented a decrease in the level of serum liver enzymes and an improvement in hepatic steatosis, necroinflammation and fibrosis 1, 3, 92 . These studies suggest that this drug might be of some benefit in NASH and has a very good safety profile. However, until more definitive data are available, the impact of pentoxifylline on the histologic features of NASH remains elusive.
PUFAs. Treatment with long-chain polyunsaturated omega-3 fatty acids (n-3 PUFAs) is safe and these agents have long been approved as an adjunct to diet for the treatment of hypertriglyceridaemia. In addition, n-3 PUFAs can exert anti-arrhythmic, anti-inflammatory and antithrombotic effects 115 . At present, whether treatment with these agents confers a benefit in NAFLD is uncertain. Treatment with n-3 PUFAs might benefit NAFLD through several different mechanisms, such as decreasing lipogenesis, altering lipoprotein assembly and decreasing hepatic inflammation 116, 117 . Whether particular types of n-3 PUFAs (for example, eicosapentaenoic acid or docosahexaenoic acid) might be more beneficial than others is also uncertain. In addition, the timing of the treatment might be an important consideration in the treatment of NAFLD, as these agents might improve liver adiposity only, and have limited or no effect on hepatic necroinflammation or fibrosis in NASH. In a phase 2 double-blind, randomized, placebo-controlled trial, treatment with low-dose (1,800 mg per day) or high-dose (2,700 mg per day) ethyl-eicosapentanoic acid for 12 months had no significant effects on the histologic features of NASH 118 . By contrast, other studies have shown a benefit of treatment with n-3 PUFAs on liver fat as assessed by MRI, and have suggested that a greater benefit in NAFLD was associated with docosahexanoic acid treatment [119] [120] [121] [122] . Additionally, the PNPLA3 Ile148Met variant has been suggested to attenuate any beneficial effect conferred by n-3 PUFA treatment in NAFLD 122 , emphasizing the need for future clinical trials testing new potential treatments for NAFLD to also consider the influence of different genotypes that might modify any treatment effect.
Effectiveness of treatment.
A 2015 Bayesian network meta-analysis combining direct and indirect treatment comparisons has assessed the comparative effectiveness of pharmacological agents for the treatment of NASH 123 . Nine randomized, controlled trials comprising 964 patients with biopsy-proven NASH, which compared treatment with vitamin E, glitazones, pentoxifylline or obeticholic acid to one another or to placebo, were identified. This meta-analysis revealed only moderate-quality evidence for the ability of glitazones, pentoxifylline and obeticholic acid to decrease hepatic necroinflammation and for pentoxifylline and obeticholic acid to improve hepatic fibrosis 123 . Taken together, these data do not enable straightforward recommendations for drug treatment of this disease.
Conclusions
From a pathophysiology perspective, the liver and kidneys share a number of pathways that are intrinsically linked to each other. Mounting data now indicate that the prevalence of CKD is markedly increased among patients with NAFLD, and that the presence and severity of NAFLD is associated with an increased incidence of CKD, independent of multiple cardiorenal risk factors (including the features of metabolic syndrome).
Taken together, these findings clearly suggest that patients with NAFLD should be screened for CKD and, similarly, that clinicians should consider whether patients with CKD might also have NAFLD. To date, no licensed treatments for NAFLD exist, but in affected patients lifestyle changes (with weight loss or increases in physical activity) and early and aggressive treatments of all the coexisting cardiometabolic risk factors might help to prevent or slow the development and progression of CKD.
We suggest that patients with NAFLD and renal dysfunction should be treated early by a multidisciplinary team that involves specialists in hepatology, diabetes, cardiology and nephrology. However, large randomized, double-blind, placebo-controlled trials that focus on treatments for liver disease in NAFLD with incident CKD outcomes are needed to definitively assess the existence of a causal relationship between NAFLD and the development and progression of CKD.
